Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
ALK‐negative
CD15
CD30
anaplastic large cell lymphoma
peripheral T‐cell lymphoma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
revised:
19
03
2024
received:
12
10
2023
accepted:
20
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
13
4
2024
Statut:
aheadofprint
Résumé
Peripheral T-cell lymphomas (PTCL) are morphologically and biologically heterogeneous and a subset expresses CD30, including anaplastic large cell lymphomas (ALCL) and a minority of PTCL, not otherwise specified (PTCL, NOS). ALCL with ALK translocations (ALCL, ALK+) are readily identified by routine diagnostic methods, but differentiating ALCL without ALK translocation (ALCL, ALK-) and PTCL, NOS expressing CD30 (PTCL CD30+) can be challenging. Furthermore, rare PTCL co-express CD30 and CD15 (PTCL CD30+CD15+); some resemble ALCL, ALK- while others resemble classic Hodgkin lymphoma. To explore the relationship between PTCL CD30+CD15+ and ALCL, ALK-, we analysed 19 cases of PTCL with CD30 expression, previously diagnosed as ALCL, ALK- (nine cases) and PTCL CD30+CD15+ (10 cases) for DUSP22/IRF4 rearrangements, coding RNA expression and selected transcriptome analysis using the NanoString nCounter gene expression analysis platform. Unsupervised clustering showed no clear segregation between ALCL, ALK- and PTCL CD30+CD15+. Three cases previously classified as PTCL CD30+CD15+ showed DUSP22/IRF4 rearrangements, favouring a diagnosis of ALCL, ALK-. Our results suggest that cases previously designated PTCL CD30+CD15+, likely fall within the spectrum of ALCL, ALK-; additionally, a subset of ALCL, ALK- with DUSP22/IRF4 rearrangement expresses CD15, consistent with previous reports and expands the immunophenotypic spectrum of this lymphoma subgroup.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). Lyon: International Agency for Research on Cancer; 2017.
Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK‐negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480.
Buchan SL, Al‐Shamkhani A. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF‐κB signaling. PLoS ONE. 2012;7(9):e45244.
Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90(2):157–164.
Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T‐cell lymphomas. Haematologica. 2013;98(8):e81–e82.
Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large‐cell lymphoma within peripheral T‐cell neoplasms. J Clin Oncol. 2010;28(9):1583–1590.
Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, et al. Identification of a 3‐gene model as a powerful diagnostic tool for the recognition of ALK‐negative anaplastic large‐cell lymphoma. Blood. 2012;120(6):1274–1281.
Bisig B, de Reynies A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, et al. CD30‐positive peripheral T‐cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98(8):1250–1258.
Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F, et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T‐cell lymphoma. Blood. 2013;122(15):2683–2693.
Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S. Peripheral T‐cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27(12):1513–1522.
Pack SD, Zhuang Z. Fluorescence in situ hybridization: application in cancer research and clinical diagnostics. Methods Mol Med. 2001;50:35–50.
Lawnicki LC, Rubocki RJ, Chan WC, Lytle DM, Greiner TC. The distribution of gene segments in T‐cell receptor gamma gene rearrangements demonstrates the need for multiple primer sets. J Mol Diagn. 2003;5(2):82–87.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57(1):289–300.
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. https://www.R‐project.org/
Langmead B, Salzberg SL. Fast gapped‐read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–359.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA‐seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511–515.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014;15(12):550.
Menter T, Tzankov A, Dirnhofer S. The tumor microenvironment of lymphomas: insights into the potential role and modes of actions of checkpoint inhibitors. Hematol Oncol. 2020;39:3–10.
Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, et al. Role of the tumor microenvironment in mature B‐cell lymphoid malignancies. Haematologica. 2016;101(5):531–540.
Gaulard P, de Leval L. The microenvironment in T‐cell lymphomas: emerging themes. Semin Cancer Biol. 2014;24:49–60.
Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen‐Lindsberg ML, et al. T‐cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104(2):338–346.
Cho J, Kim SJ, Park W‐Y, Kim J, Woo J, Kim G, et al. Immune subtyping of extranodal NK/T‐cell lymphoma: a new biomarker and an immune shift during disease progression. Mod Pathol. 2020;33(4):603–615.
Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. STAT3 mutations are frequent in CD30+ T‐cell lymphomas and T‐cell large granular lymphocytic leukemia. Leukemia. 2013;27(11):2244–2247.
Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions Lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–532.
Andersson EI, Brück O, Braun T, Mannisto S, Saikko L, Lagström S, et al. Mutation is associated with STAT3 activation in CD30. Cancers (Basel). 2020;12(3):702–718.
King RL, Dao LN, McPhail ED, Jaffe ES, Said J, Swerdlow SH, et al. Morphologic features of ALK‐negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol. 2016;40(1):36–43.
Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, et al. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with. Blood. 2018;132(13):1386–1398.
Onaindia A, de Villambrosía SG, Prieto‐Torres L, Rodríguez‐Pinilla SM, Montes‐Moreno S, González‐Vela C, et al. Rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers. Haematologica. 2019;104(4):e158–e162.
Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico‐pathologic significance in peripheral T‐cell lymphomas. Expert Rev Hematol. 2021;14(8):777–787.
Fitzpatrick MJ, Massoth LR, Marcus C, Vergilio JA, Severson E, Duncan D, et al. JAK2 rearrangements are a recurrent alteration in CD30+ systemic T‐cell lymphomas with anaplastic morphology. Am J Surg Pathol. 2021;45(7):895–904.
Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol. 2003;119(2):205–212.
Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, et al. CD30‐positive T‐cell lymphomas co‐expressing CD15: an immunohistochemical analysis. Int J Oncol. 2003;22(2):319–324.
Medeiros LJ, Elenitoba‐Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127(5):707–722.
Qiu L, Tang G, Li S, Vega F, Lin P, Wang SA, et al. DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK‐negative anaplastic large cell lymphoma. Haematologica. 2023;108(6):1604–1615.